Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Trump's Opioid Commission Asks FDA To Boost Post-Market Vigilance

Nov 02 2017

• By Brenda Sandburg

People running from dangerous pills

Related Content

Declaring Opioid Emergency, Trump Touts FDA Actions, NIH-Industry Partnerships

Oct 27 2017

Indivior's Monthly Injectable Buprenorphine Wins Panel Backing; US FDA May Limit Dosage

Nov 01 2017

FDA's Opioid Programs: After Training, What's The Next Step?

Oct 05 2017

White House Opioid Report Urges Better Access To Overdose Treatment; Mandatory Prescriber Education

Aug 03 2017

Braeburn's Buprenorphine Clears Advisory Committee, But US FDA Likely To Limit Dosage

Nov 02 2017

Related Companies

Purdue Pharma L.P.

Indivior plc

Apple Tree Partners

Additional Topics

United States Post Market Regulation & Studies Policy Neurology BioPharmaceutical

More from Post-Marketing Regulation & Studies

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window